COGT Cogent Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COGT

Price (delayed)

$7.53

Market cap

$782.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.42

Enterprise value

$748.09M

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed ...

Highlights
The company's debt fell by 4.1% YoY
The company's net income fell by 37% YoY and by 8% QoQ
Cogent Biosciences's quick ratio has decreased by 28% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of COGT
Market
Shares outstanding
103.91M
Market cap
$782.47M
Enterprise value
$748.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$192.41M
EBITDA
-$188.82M
Free cash flow
-$156.42M
Per share
EPS
-$2.42
Free cash flow per share
-$1.96
Book value per share
$2.99
Revenue per share
$0
TBVPS
$3.93
Balance sheet
Total assets
$313.44M
Total liabilities
$55.64M
Debt
$18.85M
Equity
$257.8M
Working capital
$232.6M
Liquidity
Debt to equity
0.07
Current ratio
7.09
Quick ratio
6.96
Net debt/EBITDA
0.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-58.1%
Return on equity
-67.9%
Return on invested capital
-100.6%
Return on capital employed
-69.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
3.29%
1 week
25.08%
1 month
9.29%
1 year
-33.83%
YTD
28.06%
QTD
12.05%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$208.13M
Net income
-$192.41M
Gross margin
N/A
Net margin
N/A
COGT's operating income is down by 41% year-on-year and by 7% since the previous quarter
The company's net income fell by 37% YoY and by 8% QoQ

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 3.9% QoQ
The P/B is 40% above the 5-year quarterly average of 1.8 but 3.1% below the last 4 quarters average of 2.6
The company's equity fell by 15% QoQ

Efficiency

How efficient is Cogent Biosciences business performance
COGT's return on invested capital is up by 32% year-on-year and by 4.2% since the previous quarter
The company's return on equity fell by 27% YoY and by 8% QoQ
The ROA has contracted by 25% YoY and by 7% from the previous quarter

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
Cogent Biosciences's quick ratio has decreased by 28% YoY and by 13% from the previous quarter
COGT's current ratio is down by 28% year-on-year and by 14% since the previous quarter
The company's debt is 93% lower than its equity
Cogent Biosciences's debt to equity has increased by 17% QoQ but it has decreased by 13% YoY
The company's equity fell by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.